Cinclus Pharma: Patient screening completed in Phase III study - Redeye

Redeye briefly comments on Cinclus’ announcement that patient screening has been successfully completed in the pivotal Phase III HEEALING1 study. We view the news as an encouraging operational milestone that reduces execution risk, confirms that recruitment has progressed according to plan, and keeps the company on track to deliver topline results in Q4 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1170998/cinclus-pharma-patient-screening-completed-in-phase-iii-study?utm_source=finwire&utm_medium=RSS